DelfaGLP-1 Atlas

Lead sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

11 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

11

Trials led

6

Active

1,545

Total enrollment

11

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 3
2
Phase 4
6
Not applicable
3

Trials by status

By invitation
1
Recruiting
4
Active, not recruiting
1
Completed
3
Unknown
2

Trials led

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)BMI ≥20Ph 3Recruiting420
LIGHT-MCIBMI ≥19not applicableActive, not recruiting396
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery—Ph 3Recruiting260
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryBMI ≥28Ph 4Completed100
Antidiabetic Effects on Intrahepatic FatBMI 20-35Ph 4Completed87
Evaluating Anti-Obesity Medications 6 Months After Metabolic SurgeryBMI ≥28Ph 4Recruiting60
Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight ControlBMI ≤37.5Ph 4Unknown60
Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM PatientsHbA1c 7-10%not applicableUnknown58
A Comparison of Exenatide and Insulin Glargine—Ph 4Completed44
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver DiseaseBMI 25-35Ph 4By invitation36
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists—not applicableRecruiting24